Fc Variant Amino Acid Modifications for Antibody Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies have limited therapeutic efficacy against cancer due to suboptimal Fc region interactions with Fcγ receptors, leading to inadequate effector functions such as ADCC and ADCP, and face challenges in production efficiency and cost, with existing production methods being costly and capacity-constrained.
Innovation Solution
Development of optimized Fc variants with specific amino acid modifications at positions like 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, and 328 to enhance binding affinity to FcγRs and improve effector functions, along with methods for engineering and producing these variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody production methods are used, then production capacity is limited and costs are high, but the therapeutic efficacy against cancer is insufficient due to suboptimal Fc region interactions
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the Fc region (positions 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, and 328) to optimize binding affinity to FcγRs. These targeted mutations at specific positions transform the Fc region's interaction properties, enhancing effector functions while maintaining production capabilities through standardized biopharmaceutical manufacturing processes.
2Reliability
If Fc region amino acid modifications are made to enhance binding affinity to FcγRs, then effector functions such as ADCC and ADCP are improved, but the complexity of antibody engineering increases
Solution Approach 1:
The patent applies local quality by making targeted amino acid modifications at specific positions within the Fc region rather than redesigning the entire antibody molecule. Each position (230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, and 328) is optimized independently to enhance binding affinity to specific FcγR subtypes, thereby improving effector functions like ADCC and ADCP with controlled, localized changes rather than comprehensive redesign.
Solution Approach 2:
The Fc region is segmented into specific positions and residues that can be independently modified. The patent identifies and optimizes specific amino acid positions within the Fc region, allowing systematic engineering of binding affinity at discrete locations. This segmentation enables modular approach to antibody engineering where each position can be optimized for specific FcγR interactions without affecting the entire antibody structure.
3Reliability
If existing antibody therapeutics are produced at current capacity, then production costs remain high, but the availability of advanced therapies with optimized Fc variants is limited
Solution Approach 1:
The patent applies parameter changes by optimizing specific amino acid residues in the Fc region to enhance therapeutic potency through improved FcγR binding affinity. These targeted mutations at positions 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, and 328 enable advanced therapies with superior effector functions that can be produced using established biopharmaceutical manufacturing processes, potentially reducing costs through standardized production while maintaining high therapeutic value.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized Fc variants exhibit enhanced ADCC activity and improved binding affinity to FcγRs, leading to increased therapeutic potency against cancer cells and more efficient production methods, reducing production costs and increasing availability of antibody therapeutics.
Implementation Method 1
enhance binding affinity to FcγRs and improve effector functions
Data Source
AI summary
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.